220
Participants
Start Date
June 30, 2009
Primary Completion Date
October 31, 2011
Study Completion Date
January 31, 2012
EZN-2208, Cetuximab and Irinotecan
"Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C)."
Location# 035, New York
Location# 002, New York
Location# 007, The Bronx
Location # 030, Buffalo
Location# 037, Lancaster
Location# 003, Newark
Location# 024, Winston-Salem
Location# 001, Chapel Hill
Location# 020, Goldsboro
Location# 018, Greenville
Location# 005, Marietta
Location# 067, Haifa
Location# 047, Orlando
Location# 022, Port Saint Lucie
Location# 004, Memphis
Location# 008, Columbus
Location# 071, Kfar Saba
Location #050, Terre Haute
Location# 069, Tel Litwinsky
Location# 070, Tel Aviv
Location# 066, Tel-Aviv
Location# 068, Be’er Ya‘aqov
Location #038, Houston
Location# 021, San Antonio
Location# 011, Lubbock
Location# 072, Beersheba
Location# 053, Los Angeles
Location# 046, Long Beach
Location# 073, Jerusalem District
Location# 051, Northridge
Location# 045, Pomona
Location# 042, Alhambra
Location# 044, Fullerton
Location # 048, Santa Barbara
Location # 049, Santa Barbara
Location # 043, Bakersfield
Location# 052, Santa Maria
Location #027, Stanford
Location #033, Tucson
Location# 019, La Jolla
Location# 009, Chicago
Location# 029, Worcester
Location #031, Lebanon
Location# 076, Ottawa
Location # 079, Toronto
Location# 077, Montreal
Location# 074, Montreal
Location# 055, Rimouski
Location# 041, Leiden
Location # 040, Rotterdam
Location #065, Dorchester
Location # 083, London
Location# 057, London
Location# 054-2, London
Location #061, London
Location# 064, Manchester
Location# 056, Edinburgh
Location# 062, Glasgow
Location# 054, Sutton
Location# 063, Leeds
Lead Sponsor
Enzon Pharmaceuticals, Inc.
INDUSTRY